Strong suppression of inflammation in allergic asthma has been achieved in phase I/II studies using interleukin-4 receptor subunit alpha (IL-4Ra) antagonists with lipocalin-1 nanocarriers. This evidence concerns the gene LCN1 and allergic asthma.